Exclusive Lecture - Pelvic Floor Imaging by Vikas Shah FREE OFFER ENDS TODAY!

Pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma makes up the vast majority (~90%) of all pancreatic neoplasms and remains a disease with a very poor prognosis and high morbidity.

On imaging, it usually presents as a hypodense mass on CT that is poorly marginated, which may encase vessels and the common bile duct.

Pancreatic cancer accounts for 22% of all deaths due to gastrointestinal malignancy, and 5% of all cancer deaths 1. In general, it is a malignancy of the elderly with over 80% of cases occurring after the age of 60 1.

Risk factors include:

Perhaps surprisingly there is only a weak if at all present association with heavy alcohol consumption 1.

Three precursor lesions for pancreatic adenocarcinoma have been identified 8:

Cancerous cells arise from the pancreatic ductal epithelium. As the majority of tumors (90%) 1 are not resectable, diagnosis is usually achieved with imaging (typically CT scan) although laparoscopy is often required to confirm resectability 1,2. The key to accurate staging is the assessment of the SMA and celiac axis, which if involved exclude the patient from any attempted resection 1,2.

  • head and uncinate process: two-thirds of cases
  • body and tail: one-third of cases 1

Please see pancreatic ductal adenocarcinoma staging.

Recurrence is probably better estimated by a risk score than by staging10

If large enough may demonstrate a reverse impression on the duodenum: Frostburg inverted 3 sign or a wide duodenal sweep.

Findings are non-specific and include:

CT is the workhorse of pancreatic imaging. Typically ductal adenocarcinomas appear as poorly defined masses with extensive surrounding desmoplastic reaction. They enhance poorly compared to adjacent normal pancreatic tissue and thus appear hypodense on arterial phase scans in 75-90% of cases, but may become isodense on delayed scans 1 (thus the need for multiple phase scanning when pancreatic cancer is the clinical question). Double duct sign may be seen.

CT correlates well with surgical findings in predicting unresectability (positive predictive value of 89-100% 3). The most important feature to assess locally is the relationship of the tumor to surrounding vessels (SMA and celiac axis). If the tumor surrounds a vessel by more than 180 degrees, then it is deemed T4 disease and is unresectable 3.

Signal characteristics include:

  • T1: hypointense cf. normal pancreas 5
  • T1 FS: hypointense cf. normal pancreas 5 
  • T1 + C (Gd): slower enhancement than the normal pancreas, therefore dynamic injection with fat saturation with arterial phase imaging is ideal
  • T2/FLAIR: variable (therefore not very useful), depending on the amount of reactive desmoplastic reaction 1,5
  • MRCP: double duct sign may be seen

Most tumors are not resectable at diagnosis.

Surgery for stage I and II (see staging of pancreatic cancer) does offer the chance of cure, though with high morbidity (20-30%) and mortality (5%) 3. Resection is performed with a Whipple operation.

Even when resection is possible, the majority of patients succumb to recurrence, with only a doubling of survival in operated patients 1, from 5% to 10% at 5 years 4. At 12 months following the diagnosis, almost a quarter of the patients will have died 4.

General imaging differential considerations include:

Pancreatic pathology

Article information

rID: 6736
Synonyms or Alternate Spellings:
  • Pancreatic ADK
  • Pancreas ADK
  • Ductal adenocarcinoma of pancreas
  • Pancreatic ductal adenocarcinoma (PDAC)
  • Pancreatic carcinoma
  • Pancreatic ductal cancer
  • Pancreatic adenocarcinoma
  • Ductal carcinoma of pancreas
  • Carcinoma of pancreas
  • Ductal carcinoma of the pancreas

ADVERTISEMENT: Supporters see fewers/no ads

Cases and figures

  • Figure 1: gross pathology
    Drag here to reorder.
  • Case 1
    Drag here to reorder.
  • Case 2
    Drag here to reorder.
  • Case 3: with double duct sign
    Drag here to reorder.
  • Case 4: with portal vein invasion
    Drag here to reorder.
  • Case 5
    Drag here to reorder.
  • Case 6: adenocarcinoma
    Drag here to reorder.
  • Case 7
    Drag here to reorder.
  • Case 8: unicinate process carcinoma
    Drag here to reorder.
  • Case 9
    Drag here to reorder.
  • Case 10: with mass effect shown on upper GI study
    Drag here to reorder.
  • Case 11: pancreatic head adenocarcinoma
    Drag here to reorder.
  • Case 12
    Drag here to reorder.
  • Case 13: biopsy proven adenocarcinoma
    Drag here to reorder.
  • Case 14
    Drag here to reorder.
  • Case 15: T4
    Drag here to reorder.
  • Case 16
    Drag here to reorder.
  • Case 17: T4, uncinate process, bulky nodal disease
    Drag here to reorder.
  • Case 18: uncinate process
    Drag here to reorder.
  • Case 19: T4 encasing celiac trunk
    Drag here to reorder.
  • Case 20: presenting with pancreatitis
    Drag here to reorder.
  • Updating… Please wait.

     Unable to process the form. Check for errors and try again.

     Thank you for updating your details.